WP
ANTX icon

Woodline Partners’s AN2 Therapeutics ANTX Stock Holding History

Woodline Partners’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.4M Buy
993,671
+847,700
+581% +$1.75M 0.01% 728
2025
Q4 		$166K Buy
+145,971
New +$170K ﹤0.01% 1003
2023
Q1 		– Sell
-107,300
Closed -$1.02M – 632
2022
Q4 		$1.02M Buy
107,300
+31,155
+41% +$417K 0.01% 541
2022
Q3 		$1.32M Sell
76,145
-31,155
-29% -$363K 0.02% 511
2022
Q2 		$832K Sell
107,300
-42,700
-28% -$565K 0.01% 532
2022
Q1 		$2.26M Buy
+150,000
New +$2.28M 0.04% 365

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Woodline Partners's ANTX Position: Q1 2026 in Review

Woodline Partners increased its AN2 Therapeutics (ANTX) stake by 581% in Q1 2026, buying an estimated $1.75M and bringing the position to 993,671 shares worth $3.4M. The position accounts for 0.01% of the portfolio, ranked #728.

Woodline Partners first reported a position in ANTX in Q1 2022 and has held it in 6 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Woodline Partners held 993,671 shares of AN2 Therapeutics worth $3.4M as of Q1 2026.
  • Woodline Partners bought 847,700 AN2 Therapeutics shares in Q1 2026, an estimated $1.75M.
  • AN2 Therapeutics made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #728 holding.
  • Woodline Partners first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 6 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.